---
document_datetime: 2023-09-21 22:17:55
document_pages: 17
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/nutropinaq-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
document_name: nutropinaq-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 10.3254424
conversion_datetime: 2025-12-19 05:32:09.774928
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.1-arm64-arm-64bit-Mach-O
---
## NutropinAq

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                           | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| N/0079               | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                | 20/07/2023                          |                                             | PL                               |           |
| II/0077              | C.I.11.b - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Implementation of | 06/07/2023                          | n/a                                         |                                  |           |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    | change(s) which require to be further substantiated by new additional data to be submitted by the MAH where significant assessment is required   |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| N/0076             | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                 | 02/03/2022 |            | PL          |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| PSUSA/2772/ 202003 | Periodic Safety Update EU Single assessment - somatropin                                                                                         | 10/12/2020 | 18/02/2021 | SmPC and PL | In view of available data on risk(s) from clinical trial(s), the literature, spontaneous reports including in some cases a close temporal relationship, a positive de-challenge and/or re-challenge, the PRAC Rapporteur considers a causal relationship between somatropin and acute pancreatitis is at least a reasonable possibility. The PRAC Rapporteur concludes that Section 4.4 of the SmPC of products containing somatropin should be amended to add a warning on pancreatitis. Additionally, the PRAC Rapporteur considers a causal relationship between somatropin and gynecomastia is established and concludes that section 4.8 of the SmPC of products containing somatropin should be amended, to add the adverse reaction gynecomastia with a frequency uncommon. The Package leaflet is updated accordingly. |
| IA/0075            | A.7 - Administrative change - Deletion of manufacturing sites                                                                                    | 21/12/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0073            | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                 | 16/04/2020 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |

<div style=\"page-break-after: always\"></div>

| IA/0072   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 21/01/2020   | 18/02/2021   | SmPC, Annex II, Labelling and PL   |
|-----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------------------|
| IA/0071   | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 06/09/2018   | 23/08/2019   | SmPC, Annex II, Labelling and PL   |
| IA/0070   | A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 23/05/2018   | n/a          |                                    |
| II/0069/G | This was an application for a group of variations. II: C.I.11: Submission of an updated RMP version 3.0 in order to include formatting in accordance with the new RMP template and to include updates from the post-approval safety study (PASS) International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program For NutropinAq. II: C.I.13: Submission of the final report from International Cooperative Growth Study (iNCGS) Post Marketing Surveillance Program For NutropinAq. This study collected long-term safety and effectiveness data on NutropinAq during treatment of paediatric growth disorders for which growth hormone is indicated. C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation C.I.13 - Other variations not specifically covered | 12/04/2018   | n/a          |                                    |

<div style=\"page-break-after: always\"></div>

|                    | of studies to the competent authority                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |            |             |                                                                                                                                            |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/2772/ 201703 | Periodic Safety Update EU Single assessment - somatropin                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 14/12/2017 | 22/02/2018 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) ' for PSUSA/2772/201703. |
| II/0068/G          | This was an application for a group of variations. B.II.b.2.b) To add Roche Pharma AG, Emil-Barell-Strasse 1, Grenzach-Wyhlen, Baden-Wuerttemberg, 79639, Germany as an alternative site for the quality control of the test parameter of potency by the cell proliferation assay of the finished product NutropinAq 10mg/2ml solution for injection. B.II.d.2.d) Minor changes to the test procedure of cell proliferation assay for the finished product to incorporate enhanced system suitability to determine the potency of a sample by full-curve parallel line analysis using dose-response curves generated for the samples and standards. B.I.b.2.e) Minor changes to the test procedure of cell proliferation assay for the active substance Somatropin to incorporate enhanced system suitability to determine the potency of a sample by full-curve parallel line analysis using dose-response curves generated for the samples and standards. B.I.b.2.e - Change in test procedure for AS or starting | 23/11/2017 | n/a        |             |                                                                                                                                            |

<div style=\"page-break-after: always\"></div>

|                    | the AS or a starting material/intermediate B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   |            |     |                                   |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0066/G          | This was an application for a group of variations. B.I.b.1.b - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Tightening of specification limits B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an                                                                                                                                      | 25/05/2017 | n/a |                                   |
| II/0065            | B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method                                                                                                                                                                                     | 13/10/2016 | n/a |                                   |
| PSUSA/2772/ 201509 | Periodic Safety Update EU Single assessment - somatropin                                                                                                                                                                                                                                                                                                                                                                                                   | 13/05/2016 | n/a | PRAC Recommendation - maintenance |

<div style=\"page-break-after: always\"></div>

| IB/0064   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of                                                                                                                                                                                                                                                                                                                                                                                                                      | 27/04/2016   | n/a        |    | the AS                       |
|-----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|----|------------------------------|
| IB/0063   | B.I.a.2.a - Changes in the manufacturing process of the AS - Minor change in the manufacturing process of the AS                                                                                                                                                                                                                                                                                                                                                                                                               | 16/03/2016   | n/a        |    |                              |
| II/0061/G | This was an application for a group of variations. B.I.a.1.z - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.z - Change in the manufacturing process of | 25/02/2016   | n/a        |    | the finished or intermediate |
| IB/0060   | B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                    | 07/01/2016   | n/a        |    |                              |
| N/0058    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                                                                               | 15/12/2015   | 22/02/2018 | PL |                              |
| IA/0059/G | This was an application for a group of variations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 09/12/2015   | n/a        |    |                              |

<div style=\"page-break-after: always\"></div>

<!-- image -->

|           | A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               |            |     |           |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------|
| II/0056/G | This was an application for a group of variations. B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.2.b - Changes in the manufacturing process of the AS - Substantial change to the manufacturing process of the AS which may have a significant impact on the quality, safety or efficacy of the medicinal product B.I.a.4.z - Change to in-process tests or limits applied during the manufacture of the AS - Other variation B.I.b.1.z - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing | 24/09/2015 | n/a | processes |

<div style=\"page-break-after: always\"></div>

|                    | the finished or intermediate product - Minor change in the manufacturing process B.II.d.1.d - Change in the specification parameters and/or limits of the finished product - Deletion of a non-significant specification parameter B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)   |            |     |                                   |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IAIN/0057          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                             | 02/02/2015 | n/a |                                   |
| PSUSA/2772/ 201403 | Periodic Safety Update EU Single assessment - somatropin                                                                                                                                                                                                                                                                                                                    | 06/11/2014 | n/a | PRAC Recommendation - maintenance |
| IAIN/0054          | C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location                                                                                                                                                                                                             | 04/07/2014 | n/a |                                   |
| IA/0053/G          | This was an application for a group of variations. B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished                  | 09/12/2013 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

|           | procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                    |            |     | product - Minor changes   |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|---------------------------|
| IB/0052   | B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                          | 29/11/2013 | n/a |                           |
| IA/0051/G | application for a group of variations. B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - Deletion of a non-significant in-process test B.II.b.5.c - Change to in-process tests or limits applied during the manufacture of the finished product - non-significant in-process test | 21/11/2013 | n/a | This was an Deletion of a |
| IA/0049   | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an                                                                                                                                                                                                                                                                                                                                                                                         | 20/06/2013 | n/a |                           |

<div style=\"page-break-after: always\"></div>

|           | approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |            |            |                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|
| II/0048   | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 25/04/2013 | 06/05/2014 | SmPC, Annex II, Labelling and PL |
| II/0043/G | This was an application for a group of variations. Additional site for the manufacture and quality control of the finished product B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release, batch control, and secondary packaging, for biological/immunological medicinal products. B.II.b.1.b - Replacement or addition of a manufacturing site for the FP - Primary packaging site B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation | 21/06/2012 | 21/06/2012 |                                  |
| IB/0047   | B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 07/05/2012 | n/a        |                                  |
| IB/0046   | B.II.b.2.a - Change to batch release arrangements                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 04/05/2012 | n/a        |                                  |

<div style=\"page-break-after: always\"></div>

|          | and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                                                                                 |            |            |                       |                                                                                              |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|----------------------------------------------------------------------------------------------|
| IB/0045  | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                               | 04/05/2012 | n/a        |                       |                                                                                              |
| IB/0044  | B.II.b.2.a - Change to batch release arrangements and quality control testing of the FP - Replacement or addition of a site where batch control/testing takes place                                                                                                                                                                                                                                                                                                                                                               | 04/05/2012 | n/a        |                       |                                                                                              |
| IA/0042  | B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished product - Tightening of in-process limits                                                                                                                                                                                                                                                                                                                                                                                        | 02/03/2012 | n/a        |                       |                                                                                              |
| A20/0040 | Article 20 Review On 10 December 2010, the European Commission initiated a procedure under Article 20 of Regulation (EC) No 726/2004 for somatropin-containing medicinal products authorised in the centralised procedure and requested the CHMP to assess all the available data and its impact on the risk benefit balance for somatropin-containing medicinal products and to give its opinion on measures necessary to ensure the safe and effective use of these medicinal products and whether the marketing authorisations | 15/12/2011 | 02/03/2012 | SmPC, Annex II and PL | Please refer to the Assessment Report: NutropinAq-H-315-A20-40-Assessment Report-Article 20. |

<div style=\"page-break-after: always\"></div>

|         | suspended or revoked. The scope of the review was to assess the long-term safety of growth hormone treatments in light of the emerging safety data from the French SAGHE study in particular with regards the potential increased risk of mortality due to diseases of the circulatory system, bone tumours and subarachnoid or intracerebral haemorrhage in children and when high doses are used.                                                                  |            |            |             |             |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|-------------|
| N/0041  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                                                                                                                                                                                                                                                                                                     | 31/05/2011 | n/a        | PL          |             |
| II/0038 | C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, clinical or pharmacovigilance data                                                                                                                                                                                                                                                                                                                | 17/03/2011 | 14/04/2011 | SmPC and PL |             |
| II/0039 | This type II variation concerned an update of section 4.5 of the SPC to add information regarding patients with adrenal insufficiency, interaction between somatropin and glucocorticoid replacement therapy and to add a minor clarification regarding Cytochrome P450. The Package Leaflet has been updated accordingly. C.I.4 - Variations related to significant modifications of the SPC due in particular to new quality, pre-clinical, pharmacovigilance data | 16/12/2010 | 24/01/2011 | SmPC and PL | clinical or |

<div style=\"page-break-after: always\"></div>

| II/0032   | Changes to the manufacturing process of the active substance B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological medicinal product and is not related to a protocol         | 21/10/2010   | 08/11/2010   |                          |
|-----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|--------------------------|
| II/0033   | Additional site for the storage of cell banks and raw materials B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a product | 22/07/2010   | 28/07/2010   | biological/immunological |
| IB/0037   | To change in the stability programm of the active substance. B.I.d.1.z - Stability of AS - Change in the re-test period/storage period or storage conditions - Other variation                                                                                             | 19/07/2010   | n/a          |                          |
| IB/0034   | Changes to the control of the drug substance B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                  | 31/05/2010   | n/a          |                          |

<div style=\"page-break-after: always\"></div>

| IA/0036   | Change in the control of the active substance B.I.a.4.c - Change to in-process tests or limits applied during the manufacture of the AS - Deletion of a non-significant in-process test   | 21/05/2010   | n/a        |                        |                                                                                                                                                                            |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0035   | Change to the manufacturing process of the drug substance B.I.a.4.a - Change to in-process tests or limits applied during the manufacture of the AS - Tightening of in-process limits     | 20/05/2010   | n/a        |                        |                                                                                                                                                                            |
| N/0031    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                          | 21/12/2009   | n/a        | Labelling and PL       |                                                                                                                                                                            |
| T/0030    | Transfer of Marketing Authorisation                                                                                                                                                       | 03/07/2009   | 29/07/2009 | SmPC, Labelling and PL | Transfer of Marketing Authorisation for NutropinAq from Ipsen Limited to Ipsen Pharma.                                                                                     |
| N/0029    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                          | 16/01/2009   | n/a        | PL                     |                                                                                                                                                                            |
| N/0028    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                                          | 24/04/2008   | n/a        | PL                     |                                                                                                                                                                            |
| IA/0027   | IA_05_Change in the name and/or address of a manufacturer of the finished product                                                                                                         | 20/03/2007   | n/a        |                        |                                                                                                                                                                            |
| II/0025   | This variation refers to an update of section 4.4 ''Special warnings and precautions for use'' of the Summary of Product Characteristics to add a warning                                 | 21/09/2006   | 30/10/2006 | SmPC                   | The MAH was requested to submit an overview of adverse reports on aseptic necrosis. Based on the available information, the CHMP considered that it is difficult to assess |

<div style=\"page-break-after: always\"></div>

|         | on aceptic necrosis in children with advanced renal osteodystrophy and in growth hormone deficiency. Update of Summary of Product Characteristics   |            |            |                                  | the relationship between reported cases of aseptic necrosis and therapy with growth hormone, since these events are very rare (< 0,01 %), and since this complication is more prevalent in children with chronic renal failure and growth hormone deficiency even without therapy. Nevertheless, the CHMP considered relevant to include the following warning in the SPC: ''Patients with growth hormone failure secondary to CRI should be examined periodically for evidence of progression of renal osteodystrophy. Slipped capital femoral epiphyses and aseptic necrosis of the femoral head may be seen in children with advanced renal osteodystrophy and in growth hormone deficiency, and it is uncertain whether these problems are affected by GH therapy. Physicians and parents should be alert to the development of a limp or complaints of hip or knee pain in patients treated with somatropin\".   |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0026 | Change(s) to the test method(s) and/or specifications for the finished product                                                                      | 21/09/2006 | 27/09/2006 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| II/0023 | Change(s) to the test method(s) and/or specifications for the finished product                                                                      | 27/04/2006 | 05/05/2006 |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| R/0021  | Renewal of the marketing authorisation.                                                                                                             | 26/01/2006 | 21/03/2006 | SmPC, Annex II, Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| IA/0022 | IA_07_a_Replacement/add. of manufacturing site: Secondary packaging site                                                                            | 28/10/2005 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |
| N/0020  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                    | 12/10/2005 | n/a        | PL                               |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      |

<div style=\"page-break-after: always\"></div>

| II/0014   | Change(s) to the manufacturing process for the active substance                                                                                                        | 21/04/2005   | 02/05/2005   |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0012   | Change(s) to the manufacturing process for the finished product                                                                                                        | 21/04/2005   | 02/05/2005   |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0010   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                         | 21/04/2005   | 02/05/2005   |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| N/0018    | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)                                                                       | 11/03/2005   | n/a          | Labelling and PL |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0013   | Change(s) to the test method(s) and/or specifications for the active substance                                                                                         | 17/02/2005   | 25/02/2005   |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0011   | Quality changes                                                                                                                                                        | 17/02/2005   | 25/02/2005   |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| IB/0017   | IB_38_b_Change in test procedure of finished product - minor change, biol. active subst./excipient                                                                     | 21/12/2004   | n/a          |                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| II/0009   | Update of section 4.4 of SPC and relevant section of the PL following the assessment of the 5th PSUR. Update of Summary of Product Characteristics and Package Leaflet | 21/10/2004   | 06/12/2004   | SmPC and PL      | The SPC and PL were updated with warning stating that Nutropin Aq is not indicated for the long term treatment of paediatric patients who have growth failure due to genetically confirmed Prader-Willi syndrome, unless they also have a diagnosis of growth hormone deficiency. It was also highlighted that there have been reports of sleep apnoea and sudden death after initiating therapy with growth hormone in paediatric patients with Prader-Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnoea, |

<div style=\"page-break-after: always\"></div>

|         |                                                                                                  |            |            |                        | or unidentified respiratory infection.   |
|---------|--------------------------------------------------------------------------------------------------|------------|------------|------------------------|------------------------------------------|
| IA/0008 | IA_47_c_Deletion of a pack size(s)                                                               | 02/09/2004 | n/a        | SmPC, Labelling and PL |                                          |
| N/0007  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 20/08/2004 | n/a        | PL                     |                                          |
| II/0006 | New presentation(s)                                                                              | 21/01/2004 | 19/03/2004 | SmPC, Labelling and PL |                                          |
| II/0005 | Change(s) to the test method(s) and/or specifications for the finished product                   | 25/09/2003 | 30/09/2003 |                        |                                          |
| I/0004  | 17_Change in specification of the medicinal product                                              | 04/08/2003 | 20/08/2003 |                        |                                          |
| I/0003  | 01_Change in or addition of manufacturing site(s) for part or all of the manufacturing process   | 05/06/2003 | 18/07/2003 | Annex II and PL        |                                          |
| T/0002  | Transfer of Marketing Authorisation                                                              | 30/01/2003 | 24/02/2003 | SmPC, Labelling and PL |                                          |
| N/0001  | Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification) | 29/11/2002 | 18/12/2002 | PL                     |                                          |